株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

関節軟骨損傷- パイプライン製品の分析

Articular Cartilage Defect - Pipeline Review, H2 2014

発行 Global Markets Direct 商品コード 321914
出版日 ページ情報 英文 38 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.53円で換算しております。
Back to Top
関節軟骨損傷- パイプライン製品の分析 Articular Cartilage Defect - Pipeline Review, H2 2014
出版日: 2014年12月31日 ページ情報: 英文 38 Pages
概要

関節軟骨損傷は、外傷による器質障害と、進行性の器質変性(磨耗)があります。炎症、硬直、可動域の限定などが症状です。

当レポートでは、関節軟骨損傷に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

関節軟骨損傷の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究所別

パイプライン製品の概要

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究所別

治療薬の開発に従事している企業

  • Cellular Biomedicine Group, Inc.
  • MediPost Co., Ltd.
  • Vericel Corporation

治療薬の評価

  • 単独療法の製品
  • 作用機序別
  • 分子タイプ別

薬剤のプロファイル

  • human umbilical cord blood-derived mesenchymal stem cells
  • matrix-applied characterised autologous cultured chondrocytes
  • ReJoin
  • Stem Cell Therapy for Cerebral Hemorrhage and Articular Cartilage Defect
  • Stem Cell Therapy for Osteoarthritis and Articular Cartilage Defect

最新のパイプライン製品情報

開発休止中のプロジェクト

製品開発のマイルストーン

  • 注目のニュースおよびプレスリリース

付録

図表

目次
Product Code: GMDHC5924IDB

Summary

Global Markets Direct's, 'Articular Cartilage Defect - Pipeline Review, H2 2014', provides an overview of the Articular Cartilage Defect's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Articular Cartilage Defect, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Articular Cartilage Defect and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Articular Cartilage Defect
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Articular Cartilage Defect and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Articular Cartilage Defect products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Articular Cartilage Defect pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Articular Cartilage Defect
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Articular Cartilage Defect pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Articular Cartilage Defect Overview
  • Therapeutics Development
    • Pipeline Products for Articular Cartilage Defect - Overview
    • Pipeline Products for Articular Cartilage Defect - Comparative Analysis
  • Articular Cartilage Defect - Therapeutics under Development by Companies
  • Articular Cartilage Defect - Therapeutics under Investigation by Universities/Institutes
  • Articular Cartilage Defect - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Articular Cartilage Defect - Products under Development by Companies
  • Articular Cartilage Defect - Products under Investigation by Universities/Institutes
  • Articular Cartilage Defect - Companies Involved in Therapeutics Development
    • Cellular Biomedicine Group, Inc.
    • MediPost Co., Ltd.
    • Vericel Corporation
  • Articular Cartilage Defect - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • human umbilical cord blood-derived mesenchymal stem cells - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • matrix-applied characterised autologous cultured chondrocytes - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ReJoin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy for Cerebral Hemorrhage and Articular Cartilage Defect - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy for Osteoarthritis and Articular Cartilage Defect - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Articular Cartilage Defect - Recent Pipeline Updates
  • Articular Cartilage Defect - Dormant Projects
  • Articular Cartilage Defect - Product Development Milestones
    • Featured News & Press Releases
      • Sep 16, 2014: Aastrom Biosciences to Present Three-Year Data From the SUMMIT Extension Study of MACI at the 2015 American Academy of Orthopedic Surgeons Annual Meeting
      • Apr 26, 2013: Genzyme Receives CHMP Recommendation For Approval Of MACI For Treatment Of Articular Cartilage Defect
      • Oct 30, 2012: Duke Researchers Engineer Cartilage From Pluripotent Stem Cells
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Articular Cartilage Defect, H2 2014
  • Number of Products under Development for Articular Cartilage Defect - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Late Stage Development, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Products under Investigation by Universities/Institutes, H2 2014
  • Articular Cartilage Defect - Pipeline by Cellular Biomedicine Group, Inc., H2 2014
  • Articular Cartilage Defect - Pipeline by MediPost Co., Ltd., H2 2014
  • Articular Cartilage Defect - Pipeline by Vericel Corporation, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Articular Cartilage Defect Therapeutics - Recent Pipeline Updates, H2 2014
  • Articular Cartilage Defect - Dormant Projects, H2 2014

List of Figures

  • Number of Products under Development for Articular Cartilage Defect, H2 2014
  • Number of Products under Development for Articular Cartilage Defect - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2014
  • Number of Products by Top 10 Molecule Types, H2 2014
  • Number of Products by Stage and Top 10 Molecule Types, H2 2014
Back to Top